Brazilian initial experience with lung transplantation due to irreversible lung fibrosis post-COVID-19 in a national reference center: a cohort study

Página do item simplificado
dc.contributor.authorReis, Flavio Pola dos
dc.contributor.authorFernandes, Lucas Matos
dc.contributor.authorAbdalla, Luis Gustavo
dc.contributor.authorCampos, Silvia Vidal
dc.contributor.authorCamargo, Priscila Cilene Leon Bueno de
dc.contributor.authorSantos, Samuel Lucas dos
dc.contributor.authorAguiar, Ivana Teixeira de
dc.contributor.authorPires, Juliana Patricia
dc.contributor.authorCosta, Andre Nathan
dc.contributor.authorCarraro, Rafael Medeiros
dc.contributor.authorTeixeira, Ricardo Henrique de Oliveira Braga
dc.contributor.authorPêgo-Fernandes, Paulo Manuel
dc.date.accessioned2024-05-17T13:37:02Z
dc.date.available2024-05-17T13:37:02Z
dc.date.issued2022
dc.description.abstractABSTRACT BACKGROUND: Lung transplantation (LTx) has been discussed as an option for treating irreversible lung fibrosis post-coronavirus disease 2019 (COVID-19), in selected cases. OBJECTIVES: To report on the initial experience and management of end-stage lung disease due to COVID-19 at a national center reference in Brazil. DESIGN AND SETTING: Cohort study conducted at a national reference center for lung transplantation. METHODS: Medical charts were reviewed regarding patients’ demographics and pre-COVID-19 characteristics, post-LTx due to COVID-19. RESULTS: Between March 2020 and September 2021, there were 33 cases of LTx. During this period, we evaluated 11 cases of severe COVID-19-related acute respiratory distress syndrome (ARDS) that were potentially candidates for LTx. Among these, LTx was only indicated for three patients (9.1%). All of these patients were on venovenous extracorporeal membrane oxygenation (ECMO), and the procedure that they underwent was central venoarterial ECMO. All three patients were still alive after the first 30 postoperative days. However, patient #1 and patient #2 subsequently died due to fungal sepsis on the 47th and 52nd postoperative days, respectively. Patient #3 was discharged on the 30th postoperative day. CONCLUSIONS: LTx is feasible among these complex patients. Survival over the first 30 days was 100%, and this favors surgical feasibility. Nonetheless, these were critically ill patients.
dc.identifier.doi10.1590/1516-3180.2021.0842.r1.13102021
dc.identifier.issn1516-3180
dc.identifier.otherS1516-31802022000100153-scl
dc.identifier.urihttps://repositorio-aptaregional.agricultura.sp.gov.br/handle/123456789/1920
dc.relation.ispartofSao Paulo Medical Journal
dc.subjectExtracorporeal membrane oxygenation
dc.subjectLung transplantation
dc.subjectCOVID-19
dc.subjectECMO
dc.subjectLung transplant
dc.subjectEnd-stage lung disease
dc.titleBrazilian initial experience with lung transplantation due to irreversible lung fibrosis post-COVID-19 in a national reference center: a cohort study
dc.typeArtigos
oaire.citation.endPage159
oaire.citation.issue1
oaire.citation.startPage153
oaire.citation.volume140

Arquivos

Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar

Coleções

Artigos